-
European Commission approves Esmya® Type II variation, allowing a repeated course of 3-month treatment for uterine fibroids
News, Press Releases oninBudapest, Hungary, 27 January 2013: Gedeon Richter Plc. (“Richter”) announces that Esmya® 5 mg tablets (ulipristal acetate) is now licensed…
0